Biotech Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT August 31, 2022
Biotech FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva August 31, 2022
Biotech NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING August 31, 2022
Biotech BIO-TECHNE TO PRESENT AT THE MORGAN STANLEY 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE August 31, 2022
Biotech Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia August 31, 2022
Biotech FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS) August 29, 2022
Biotech Bionano Genomics Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity August 29, 2022